Petros Grivas, MD, PhD, discusses the phase 2 TROPHY U-01 trial in metastatic urothelial cancer.
Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance, associate professor, Division of Medical Oncology, University of Washington (UW) School of Medicine, clinical director, Genitourinary Cancers Program, UW Medicine, associate member, Clinical Research Division, Fred Hutchinson Cancer Center, discusses the phase 2 TROPHY U-01 trial (NCT03547973) in metastatic urothelial cancer.
Cohort 3 of TROPHY-U-01 evaluated sacituzumab govitecan-hziy (Trodelvy) plus pembrolizumab (Keytruda) in patients with metastatic urothelial cancer who progressed after platinum-based chemotherapy in the frontline setting.
Notably, this cohort included patients who received neoadjuvant or adjuvant chemotherapy if they recurred within 12 months from their last dose of chemotherapy, Grivas explains.
Patients were not eligible if they had an active autoimmune disease, and they must have recovered from prior treatment-related toxicities, Grivas continues. The eligibility criteria aimed to mirror what is typically seen with urothelial cancer in clinical practice, Grivas concludes.